Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

640

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

January 8, 2026

Study Completion Date

January 8, 2026

Conditions
Yellow Fever Immunization
Interventions
BIOLOGICAL

Yellow fever vaccine (live)

Powder and solvent for solution for injection Subcutaneous

BIOLOGICAL

YF vaccine (live)

Powder and diluent for suspension for injection Subcutaneous

Trial Locations (7)

14610

Rochester Clinical Research- Site Number : 8400005, Rochester

21205

Johns Hopkins Bloomberg School of Public Health- Site Number : 8400009, Baltimore

30030

The Hope Clinic of Emory University- Site Number : 8400006, Decatur

63104

Saint Louis University Center for Vaccine Development- Site Number : 8400001, St Louis

70119

Velocity Clinical Research-New Orleans- Site Number : 8400004, New Orleans

84109

J. Lewis Research, Inc. / Foothill Family Clinic, Salt Lake City

02818

Velocity Clinical Research - Providence- Site Number : 8400003, East Greenwich

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY